1:05 PM
 | 
Mar 04, 2019
 |  BC Extra  |  Clinical News

Ascendis jumps on Phase III readout for once-weekly growth hormone

Editor's Note: This article was updated on Mar 07, 2019 at 10:55 AM PST

Ascendis gained $51.29 (74%) to $120.60 on Monday after reporting that its TransCon Growth Hormone met the primary endpoint in the Phase III heiGHt trial to treat pediatric growth hormone deficiency. The company plans to submit a BLA to FDA in 1H20 for the once-weekly human growth hormone...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD